What we do
We are developing first-in-class small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Company News
Veralox Therapeutics Appoints Life Sciences Industry Veteran Alex Martin as Chairman of the Board of Directors
FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today... Read More
Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi Ventures
Funding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics (“Veralox”), a preclinical stage company focused on... Read More
Biotech Startups On the Rise in Frederick, Maryland
Biotech Startups On the Rise in Frederick, Maryland These four biotech startups reflect an ecosystem that is attracting founders, talent and capital. Frederick, Maryland continues... Read More
Featured Article
Meet Our Clients: Jeff Strovel, CEO of VERALOX Therapeutics
Thrombocytopenia is a big word that can carry big consequences for those struggling with rare blood disorders, especially among those using heparin to treat and... Read More